NICE
NICE recommends Takeda’s Adcetris for previously untreated systemic anaplastic large cell lymphoma
July 9, 2020Sales and Marketing Adcentris, NICE, Takeda, UK
NICE has announced it has recommended Takeda’s Adcetris (brentuximab vedotin), in combination with cyclophosphamide, doxorubicin and prednisone (CHP), for use …
NICE to recommend Roche cancer treatment
June 26, 2020Medical Communications NHS, NICE
NICE are set to recommend Roche’s Rozlytrek (Entrectinib) cancer treatment which will be the second histology drug to be recommended …
NICE knocks back Novartis’ Mayzent in secondary progressive multiple sclerosis over data gaps
June 25, 2020Sales and Marketing Mayzent, NHS, NICE, Novartis
Novartis’ Mayzent (siponimod) has been unsuccessful in securing a recommendation from NICE for use on the NHS for the treatment …
NICE greenlights Roche’s Rozlytrek for ROS1+ advanced non-small cell lung cancer
June 15, 2020Sales and Marketing NICE, Roche, Rozlytrek, UK, lung cancer
Roche’s Rozlytrek (entrectinib) has secured recommendation for NHS use in England and Wales after NICE backed the drug in final …
NICE reverses previous stance to recommend Roche’s Tecentriq in extensive-stage small-cell lung cancer
May 27, 2020Research and Development, Sales and Marketing NICE, Roche, lung cancer, tecentriq
NHS patients with treatment-naïve extensive-stage small-cell lung cancer (ES-SCLC) in England and Wales will soon have access to a new …
NICE gives thumbs-up to Roche’s Kadcyla in HER2+ breast cancer sub-population
May 7, 2020Sales and Marketing Cancer, Kadcyla, NHS, NICE, Roche, UK, breast cancer
NICE has revealed that it has recommended the NHS use of Roche’s Kadcyla (trastuzumab emtansine) for HER2+ breast cancer in …
NICE backtracks to approve Janssen’s Stelara in ulcerative colitis
April 28, 2020Manufacturing and Production, Research and Development Janssen, NICE, Stelara, ulcerative colitis
NICE has recommended Janssen’s Stelara (ustekinumab) for the treatment of moderately to severely active ulcerative colitis (UC), a move which …
Bayer’s Vitrakvi becomes first tumour-agnostic therapy approved by NICE for NHS patients with NTRK fusion+ cancer
April 21, 2020Manufacturing and Production, Sales and Marketing Bayer, Cancer, NICE, UK, Vitrakvi, tumour agnostic
Bayer’s oral TRK inhibitor Vitrakvi (larotrectinib) has just been recommended by NICE in the treatment of advanced neurotrophic tyrosine receptor …
NICE promotes Professor Gillian Leng as its new Chief Executive
March 18, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, NICE, UK, pharma
NICE, the drug watchdog for the NHS in England and Wales, has announced that it has promoted Professor Gillian Leng …
Keytruda rejected for NHS use for bladder cancer, will be removed from the Cancer Drugs Fund
March 12, 2020Sales and Marketing Cancer, Kidney cancer, MSD, NHS, NICE, blader cancer, keytruda, pharma
MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) has been knocked back by NICE for use on the NHS as a treatment for …
Teva’s Ajovy becomes first drug of its kind available on NHS for prevention of chronic migraine
March 12, 2020Sales and Marketing NICE, Teva, ajovy, migraine, pharma
NICE has announced the authorisation of Teva’s anti-CGRP drug Ajovy (fremanezumab) for the prevention of chronic migraine in adult patients …
NICE shoots down Dupixent for severe asthma
March 9, 2020Sales and Marketing Dupixent, NHS, NICE, Regeneron, Sanofi, UK, asthma
NICE, the NHS’ drug watchdog in England and Wales, has announced its decision not to recommend Sanofi and Regeneron’s IL-4 …
NICE recommends avatrombopag to treat thrombocytopenia in chronic liver disease
March 4, 2020Research and Development Avatrombopag, NHS, NICE, UK, chronic liver disease
UK drug watchdog NICE has announced its final draft guidance recommending avatrombopag for routine use on the NHS in England …
NICE recommends Celgene’s Revlimid combo for follicular lymphoma
February 27, 2020Sales and Marketing Cancer, Celgene, NICE, Revlimid, follicular lymphoma, pharma
NICE has chosen to recommend Celgene’s Revlimid (lenalidomide) for use on the NHS, it has emerged, alongside Genentech’s Rituxan (rituximab), …
NICE rejects Roche’s Polivy combo in relapsed or refractory diffuse large B-cell lymphoma
February 26, 2020Manufacturing and Production, Research and Development, Sales and Marketing NHS, NICE, Polivy, Roche
It has been revealed that UK drug watchdog NICE has chosen to reject Roche’s Polivy (polatuzumab vedotin), used alongside rituximab …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
